Search

Background Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature contains minimal research on this practice. There has been limited reporting on adverse events associated with microdosing, and the experiences of microdosers in community samples have not been categorized. Methods In the present study, we develop a codebook of microdosing benefits and challenges (MDBC) based on the qualitative reports of a real-world sample of 278 microdosers. Results We describe novel findings, both in terms of beneficial outcomes, such as improved mood (26.6%) and focus (14.8%), and in terms of challenging outcomes, such as physiological discomfort (18.0%) and increased anxiety (6.7%). We also show parallels between benefits and drawbacks and discuss the implications of these results. We probe for substance-dependent differences, finding that psilocybin-only users report the benefits of microdosing were more important than other users report. Conclusions These mixed-methods results help summarize and frame the experiences reported by an active microdosing community as high-potential avenues for future scientific research. The MDBC taxonomy reported here informs future research, leveraging participant reports to distil the highest-potential intervention targets so research funding can be efficiently allocated. Microdosing research complements the full-dose literature as clinical treatments are developed and neuropharmacological mechanisms are sought. This framework aims to inform researchers and clinicians as experimental microdosing research begins in earnest in the years to come. Electronic supplementary material The online version of this article (10.1186/s12954-019-0308-4) contains supplementary material, which is available to authorized users.

Rationale: Microdosing psychedelics – the practice of consuming small, sub-hallucinogenic doses of substances such as LSD or psilocybin – is gaining attention in popular media but remains poorly characterized. Contemporary studies of psychedelic microdosing have yet to report the basic psychiatric descriptors of psychedelic microdosers. Objectives: To examine the practices and demographics of a population of psychedelic microdosers – including their psychiatric diagnoses, prescription medications, and recreational substance use patterns – to develop a foundation on which to conduct future clinical research. Methods: Participants ( n = 909; Mage = 26.9, SD = 8.6; male = 83.2%; White/European = 79.1%) recruited primarily from the online forum Reddit completed an anonymous online survey. Respondents who reported using LSD, psilocybin, or both for microdosing were grouped and compared with non-microdosing respondents using exploratory odds ratio testing on demographic variables, rates of psychiatric diagnoses, and past-year recreational substance use. Results: Of microdosers, most reported using LSD (59.3%; Mdose = 13 mcg, or 11.3% of one tab) or psilocybin (25.9%; Mdose = 0.3 g of dried psilocybin mushrooms) on a one-day-on, two-days-off schedule. Compared with non-microdosers, microdosers were significantly less likely to report a history of substance use disorders (SUDs; OR = 0.17 (95% CI: 0.05–0.56)) or anxiety disorders (OR = 0.61 (95% CI: 0.41–0.91)). Microdosers were also more likely to report recent recreational substance use compared with non-microdosers (OR = 5.2 (95% CI: 2.7–10.8)). Conclusions: Well-designed randomized controlled trials are needed to evaluate the safety and tolerability of this practice in clinical populations and to test claims about potential benefits.

Supplemental material, Supplementary_Table for Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities by Daniel Rosenbaum, Cory Weissman, Thomas Anderson, Rotem Petranker, Le-Anh Dinh-Williams, Katrina Hui and Emma Hapke in Journal of Psychopharmacology

The complete code hierarchy is available in Additional file 1. (PDF 89 kb)

Microdosing psychedelics—the regular consumption of small amounts of psychedelic substances such as LSD or psilocybin—is a growing trend in popular culture. Recent studies on full-dose psychedelic psychotherapy reveal promising benefits for mental well-being, especially for depression and end-of-life anxiety. While full-dose therapies include perception-distorting properties, microdosing mayprovide complementary clinical benefits using lower-risk, non-hallucinogenic doses. This pre-registered study aimed to investigate whether microdosing psychedelics is related to differences in personality, mental health, and creativity. In this observational study, respondents recruited from online forums self-reported their microdosing behaviors and completed questionnaires concerning dysfunctional attitudes, wisdom, negative emotionality, open-mindedness, and mood. Respondents also performed the Unusual Uses Task to assess their creativity. Current and former microdosers scored lower on measures of dysfunctional attitudes (p < 0.001, r = − 0.92) and negative emotionality (p = 0.009, r = − 0.85) and higher on wisdom (p < 0.001, r = 0.88), openmindedness(p = 0.027, r = 0.67), and creativity (p < 0.001, r = 0.15) when compared to non-microdosing controls. These findings provide promising initial evidence that warrants controlled experimental research to directly test safety and clinical efficacy. As microdoses are easier to administer than full-doses, this new paradigm has the exciting potential to shape future psychedelic research.

The term “hypo-egoic” can refer to a variety of cognitive states, ranging from internal experiences of meditation, hypnosis, or spirituality, to overt acts of forgiveness or altruism. This chapter reviews the nascent literature on the neuroscience supporting such states, aiming to provide a more unified neural account. For parsimony, research findings are framed in terms of implicated brain networks, with particular attention as to whether networks are modulated to directly inhibit of egoic processes, or to generate competing, experientially salient, hypo-egoic states. The chapter concludes that hypo-egoic processing is not purely inhibitory in its neural architecture but often incorporates generative neural representations, enhancing sensory awareness in meditation and hypnosis, the theory of another’s mind in love and forgiveness, and vicarious enjoyment in altruistic acts. These generative processes may anchor attention and attenuate prepotent tendencies toward egoic thinking, allowing for the transcendence of self-concern in favor of some greater good.

Studies have shown that appetitive smoking-related stimuli (e.g., someone smoking) trigger significant cravings in current and abstinent smokers, which impedes their self-control capacities and promotes drug-seeking behavior. Furthermore, research suggests that this drug-seeking behavior is unaffected by exposure to aversive smoking-related stimuli, such as antismoking campaigns designed to remind users of the negative consequences of smoking. Indeed, two important clinical features of tobacco use disorder are an increased reactivity to appetitive smoking-related stimuli and a decreased reactivity to aversive smoking-related stimuli—a pattern that ultimately helps maintain smoking behavior and impede smoking cessation efforts. Neuroimaging studies have been valuable in elucidating on the mechanisms underlying these clinical features of tobacco use disorder. In this chapter, we discuss and compare the neurobiological mechanisms that promote a craving response to appetitive smoking cues, as well as the neurobiological mechanisms that hinder the ability for aversive smoking cues to have an impact on drug-seeking behavior. These fMRI findings highlight important processes underlying tobacco use disorder.

Craving is a core feature of tobacco use disorder as well as a significant predictor of smoking relapse. Studies have shown that appetitive smoking-related stimuli (e.g. someone smoking) trigger significant cravings in smokers which impedes their self-control capacities and promotes drug seeking behavior. In this review, we begin by an overview of functional magnetic resonance imaging (fMRI) studies investigating the neural correlates of smokers to appetitive smoking cues. The literature reveals a complex and vastly distributed neuronal network underlying smokers’ craving response that recruits regions involved in self-referential processing, panning/regulatory processes, emotional responding, attentional biases, and automatic conducts. We then selectively review important factors contributing to the heterogeneity of results that significantly limit the implications of these findings, namely between- (abstinence, smoking expectancies and self-regulation) and within-studies factors (severity of smoking dependence, sex-differences, motivation to quit and genetic factors). Remarkably, we found that little to no attention has been devoted to examine the influence of personality traits on the neural correlates of cigarette cravings in fMRI studies. Impulsivity has been linked with craving and relapse in substance and tobacco use, which prompted our research team to examine the influence of impulsivity on cigarette cravings in an fMRI study. We found that the influence of impulsivity on cigarette cravings was mediated by fronto-cingular mechanisms. Given the high prevalence of cigarette smoking in several psychiatric disorders that are characterized by significant levels of impulsivity, we conclude by identifying psychiatric patients as a target population whose tobacco smoking habits deserve further behavioral and neuro-imaging investigation.